Resource Center

www.lls.org/resourcecenter

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:

donate

July 19, 2012 - AML - Emerging Treatment Strategies

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: July 19, 2012
Time: 1:00 p.m. - 2:00 p.m. ET
Location: Telephone/Web
View: Program Slides 
Read: Transcript
Listen: Presentation | Q&A Session | Extended Q&A
Access: Virtual Lecture 

Topics Covered

  • Signs or symptoms of acute myeloid leukemia (AML)
  • Blood and marrow tests used to diagnose AML
  • Current and emerging treatment options
  • Treatment side effects and strategies for side effect management
  • The role of clinical trials in the continuing improvement of AML treatment outcomes
  • Information and support resources for patients and caregivers

Speaker

Wendy Stock, MD
Professor of Medicine, Section of Hematology/Oncology
Director, Leukemia Program
The University of Chicago Medicine
Chicago, IL

Questions Asked by the AML Community

  • Is there a role for molecular diagnosis as a guide to maintenance therapy, to keep a patient in remission?
  • Would you be able to comment at all on your recommendations for second transplant for high-risk groups such as FLT3 who relapsed after a first allogeneic bone marrow transplant?
  • Would a 74-year-old woman in otherwise good health ever be a candidate for a stem cell transplant?
  • What kind of research is being done and what is the success rate of using stem cells from umbilical cords?
  • Does it take longer for a person to recover from a double cord transplant?
  • Do you have any information about the Celator Trial, CPX-351? If so, could you discuss that?
  • After an original diagnosis of AML and successful treatment, the diagnosis has been modified to MDS evolved into AML. What gets treated now, the AML or the MDS?
  • After 16 months in remission, what is the risk of the disease becoming active again?

Sponsors and Supporters

This program was sponsored by The Leukemia & Lymphoma Society.

last updated on Tuesday, April 15, 2014
btn_sharethis

Get Information & Support

Contact an Information Specialist.